Urteste publishes first peer-reviewed Panuri paper

Urteste said Tuesday it published the first peer-reviewed paper on its Panuri urine test for pancreatic cancer, a milestone as the investigational device continues European clinical testing. The company also plans to present progress at ADLM 2026 in Anaheim later this month.

Why it matters: - The publication gives Urteste's Panuri program peer-reviewed scientific validation as the company pushes toward European regulatory approval. - Panuri is being developed as a non-invasive urine test for pancreatic cancer, a disease that is often found at an advanced stage. - The test could help support earlier detection of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.

What happened: - Urteste S.A. announced the publication of its first peer-reviewed scientific article on Panuri on July 22, 2026. - The paper, "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer," was published in Diagnostics. - The article describes the analytical validation of Panuri, an investigational in vitro diagnostic device. - Panuri has not yet obtained CE marking and remains in multicenter clinical performance evaluation across Europe under the IVDR.

The details: - The Panuri assay showed 89% analytical sensitivity, with a 95% confidence interval of 78.5% to 94.9%. - The assay showed 75% analytical specificity, with a 95% confidence interval of 64.8% to 83.5%. - Urteste reported high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility. - The coefficients of variation were below 10%. - Panuri measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - The newly published paper provides the scientific description of the analytical work completed during development. - The article is available in Diagnostics (2026) as the published paper. - Urteste is also developing 13 prototypes for cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - The company says those cancers together account for nearly 70% of all cancer-related deaths worldwide.

Between the lines: - The peer-reviewed paper helps move Panuri from internal development toward a broader scientific and regulatory conversation. - Urteste is pairing the publication with conference visibility, which can help the company court clinical and commercial partners. - The broader product lineup suggests Urteste is positioning its urine-based enzyme detection platform as a multi-cancer diagnostics strategy, not just a single-product effort.

What's next: - Urteste is continuing a prospective multicenter clinical performance study in patients undergoing diagnostic work-up for suspected pancreatic cancer. - The study is running at 30 clinical sites in Poland, Italy and Hungary. - The trial will include about 550 evaluable participants. - The results are intended to support the European regulatory process for Panuri under IVDR. - Urteste Management Board members will attend ADLM 2026 in Anaheim, California, from July 26-30, 2026. - The company plans to present Panuri progress, discuss the scientific publication and the clinical study, and meet potential strategic and commercial partners.

The bottom line: - Urteste is trying to turn a promising urine-based pancreatic cancer test into a clinically and commercially credible product, with peer-reviewed data now public and European trial work still underway.